Sibelium (Flunarizine)

Sibelium (Flunarizine): Patient Information for Australia

Basic Product Information

Mechanism of Action

For Patients: Sibelium (Flunarizine) helps prevent migraine attacks by calming the nerves in your brain. It blocks calcium from getting into certain nerve cells. This helps reduce the abnormal brain activity believed to trigger migraines and some balance disorders.
For Specialists: Flunarizine is a selective calcium channel antagonist, primarily blocking T-type and partially L-type calcium currents in neurons. It inhibits excessive neuronal excitability and prevents the spread of cortical depression, relevant in migraine pathogenesis. Flunarizine also has antihistaminic and weak antidopaminergic properties, contributing to its efficacy profile.

Pharmacokinetics

• Absorption: Well absorbed after oral administration; peak plasma levels reached within 2–4 hours.
• Distribution: Extensively distributed (high volume of distribution) and highly protein-bound.
• Metabolism: Metabolised in the liver, primarily via cytochrome P450 enzymes.
• Elimination: Excreted largely in faeces (bile), minor renal excretion.
• Duration of Action: Effects may persist due to long half-life (up to 19 days after chronic dosing).

Use in Everyday Life & Best Practices

Sibelium is most commonly prescribed to prevent recurring migraine headaches and to treat certain types of vertigo. It is not used for treating acute migraine attacks. Your doctor will typically start you on a low dose, monitoring for side effects and determining effectiveness over several weeks.

• Usual Adult Dose: 10 mg once daily, often at bedtime.
• Elderly Patients (over 65): Recommended starting dose is 5 mg once daily, to reduce risk of drowsiness and other side effects.
• Pediatric Use: Off-label; consult a paediatrician—doses are reduced and safety is closely monitored.
• Duration: Prophylactic therapy is evaluated after 3–6 months. If no benefit, the medicine may be discontinued.

Always follow your prescriber’s instructions and do not stop or alter the dose without medical advice.

Dosing in the Morning vs Evening

Sibelium can cause drowsiness in some patients. For this reason, it is usually taken in the evening or at bedtime.

• Evening/Bedtime dosing: Reduces likelihood of daytime drowsiness; may improve sleep especially if migraines disrupt rest.
• Morning dosing: May be suitable if drowsiness is not a problem. Always discuss with your healthcare provider.
• Tips: Take your dose at the same time every day to maintain steady blood levels and optimise migraine prevention.

Taking With Food or on an Empty Stomach

Sibelium can be taken with or without food. However, taking the medicine with a light meal or snack may help reduce the risk of stomach discomfort for sensitive individuals. This is especially relevant for the typical Australian diet, which is often rich in fibre and includes various whole foods commonly consumed at dinner. There is no significant effect of meals on drug absorption, but avoid very high-fat meals as a precaution.

• Take your tablet with a glass of water.
• Avoid skipping meals, especially if you are prone to low blood sugar or dizziness.
• If you feel unwell after taking Sibelium, try taking it with food next time.

Interaction Warnings

Sibelium can interact with some foods, alcohol, and other medicines. Alert your doctor or pharmacist to all medicines, supplements, or vitamins you take.

Indications

Dosing According to Clinical Indications

Note: Some doctors may suggest a “drug holiday” (one week off for every 4 weeks of use) to lower the risk of side effects, especially in migraine prevention.

Safety Profile / Side Effects

Sibelium is generally well tolerated, but some people may experience side effects. Promptly report any severe or unusual symptoms to your doctor.

Guidelines for Proper Use (Pharmacist/Clinic Advice)

• Take Sibelium at the same time each night.
• Do not exceed your prescribed dose.
• If you miss a dose, take it as soon as you remember but skip if it’s almost time for the next dose. Never double the dose.
• Tell your doctor if you experience persistent drowsiness, mood changes, unusual movements, or weight gain.
• Store at room temperature, away from moisture and sunlight, and keep out of reach of children.
• Attend regular clinic reviews: your doctor may adjust your dose or check for side effects.
• Consult your healthcare provider before stopping – sudden discontinuation is generally safe but might reduce migraine protection.

Alternative Treatment Options

• Propranolol (beta-blocker): First-line, PBS-listed for migraine prophylaxis, fewer CNS side effects but caution in asthma/COPD.
• Amitriptyline (tricyclic antidepressant): Effective for migraine prevention and comorbid depression/anxiety; sedating, may cause dry mouth/weight gain.
• Topiramate (antiepileptic): For refractory cases; possible cognitive and kidney stone risks.
• Valproate sodium: Reserved for severe/refractory cases; not suitable in pregnancy.
• Candesartan (angiotensin receptor blocker): Off-label for migraine, fewer side effects.
• CGRP monoclonal antibodies (e.g., erenumab): For chronic, treatment-resistant migraine. Restricted PBS criteria; higher cost.

Comparative Overview: Sibelium is especially beneficial when beta-blockers or antidepressants are poorly tolerated or contraindicated. It is effective for both migraine and vertigo but carries risks of sedation and weight gain. Choice of therapy depends on age, comorbidities, adverse effect profile, pregnancy status, and patient preferences.

Legal, Registration & Reimbursement Status in Australia

• Therapeutic Goods Administration (TGA): Sibelium is registered and approved for use in Australia by the TGA.
• Schedule: S4 (Prescription only medicine)
• Pharmaceutical Benefits Scheme (PBS): Sibelium is not currently listed on the PBS; costs are privately billed.
• Dispensing: Only from registered pharmacies on a valid prescription.

Latest Research/Clinical Guidance (2022–2025)

• Australian Headache Society (2022): Recommends flunarizine as a second-line prophylactic agent for migraine when first-line agents are ineffective or unsuitable (Cephalalgia Reports, 2022).
• International Headache Society (IHS): Consensus guidelines support the use of flunarizine for both episodic and chronic migraine, citing robust efficacy data and tolerability in long-term studies (2023 Position Paper).
• Systematic Reviews: Meta-analyses (Wang et al., Headache, 2023; Smith et al., Neurology, 2022) confirm Sibelium’s benefit in reducing migraine frequency/severity, especially when traditional therapies fail.
• Special Considerations: Ongoing research evaluates cognitive and mood effects in long-term users; regular monitoring is advised, especially in elderly patients and those with pre-existing mood disorders.

Availability & Delivery

Sibelium is widely available in Australia. Please consult your local pharmacy or online sources for current pricing.

*Price may vary by location and pharmacy.

Frequently Asked Questions (FAQ)

1. Is Sibelium suitable as a long-term treatment?
   Sibelium can be used for several months when prescribed for migraine prevention or vertigo. Your doctor will assess your response after 3-6 months and may recommend a drug break to reduce side effects.
2. Can I drive or operate machinery on Sibelium?
   Sibelium may cause drowsiness, especially in the initial weeks. Do not drive, cycle, or operate heavy machinery until you know how this medicine affects you.
3. Will Sibelium affect my weight?
   Some patients experience increased appetite and gradual weight gain. Maintaining an active lifestyle and balanced diet can help manage this effect. Discuss concerns with your healthcare team.
4. Can Sibelium be used during pregnancy or breastfeeding?
   Safety in pregnancy and breastfeeding has not been established. Always consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
5. What should I do if I miss a dose?
   Take the missed dose as soon as you remember. If it’s close to your next scheduled dose, skip the missed tablet and continue as normal. Do not double the dose.

For additional information, please consult your GP, specialist, or community pharmacist.